GEN News Highlights: Jan 21, 2011

Heads Up—Research Spending at Risk

(Page 1 of 1)

    Scientists fear that if GOP leaders succeed in cutting $100 billion or more from nondefense programs, the U.S. biomedical research community will suffer greatly. Republicans largely took over the House of Representatives during last fall’s elections by promising to cut both the size of government  and government spending. They are now moving ahead to carry out those plans.

    If the cuts go into effect new clinical trials may not be initiated and basic research that could lead to new clinical trials will not get done, an NIH scientist told GEN, speaking on conditions of anonymity. “We may lose a whole generation of scientists as current students may no longer see research as a viable career option,” he notes.

    It remains to be seen how much the GOP will actually be able to cut since the Democrats control the Senate. The budget war will loom large through 2011 and beyond, and the associated political battles will be a huge part of the national news all year.


Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll